Ozempic for Heart Disease — The New Research

Join host Julia Cartwright as she explores groundbreaking research revealing Ozempic's potential beyond weight loss—as a powerful tool against heart disease. Discover the landmark trials and stunning data suggesting semaglutide could be a game changer for cardiovascular health, all explained in plain English with Julia's signature quirky analogies.Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTVThis content was created in partnership and with the help of Artificial Intelligence AIThis episode includes AI-generated content.

Join host Julia Cartwright as she examines the unresolved questions surrounding semaglutide's cardiovascular effects. From Alberta mouse studies showing unexpected heart changes to promising March 2026 research on post-heart-attack recovery, she explores what science knows—and critically, what remains uncertain—about this groundbreaking medication's heart benefits.Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTVThis content was created in partnership and with the help of Artificial Intelligence AIThis episode includes AI-generated content.

Julia Cartwright explores groundbreaking research showing semaglutide (Ozempic/Wegovy) reduces heart failure hospitalizations by 70% in HFpEF patients—a stubborn condition affecting millions with few treatment options. The episode examines clinical trial data revealing benefits beyond weight loss, including reduced inflammation and improved heart function, marking a potential paradigm shift in cardiovascular medicine.Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTVThis content was created in partnership and with the help of Artificial Intelligence AIThis episode includes AI-generated content.

Julia Cartwright explores how the landmark SELECT trial revealed semaglutide (Ozempic/Wegovy) reduces heart attacks and strokes by 20% in 17,604 patients with cardiovascular disease—marking the first time a weight-loss drug became FDA-approved heart medicine, potentially revolutionizing cardiac care beyond traditional treatments.Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTVThis content was created in partnership and with the help of Artificial Intelligence AIThis episode includes AI-generated content.